Jonathan Riess, MD, MS

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Regeneron
    Topic:
    Lung Cancer
    Date added:
    08/05/2024
    Date updated:
    08/06/2024
    Relationship end date:
    06/01/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Sanofi
    Topic:
    Lung Cancer
    Date added:
    08/05/2024
    Date updated:
    08/06/2024
    Relationship end date:
    06/01/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Janssen
    Topic:
    Lung Cancer
    Date added:
    08/05/2024
    Date updated:
    08/06/2024
    Relationship end date:
    07/01/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Roche/Genentech
    Topic:
    Lung Cancer
    Date added:
    08/05/2024
    Date updated:
    08/06/2024
    Relationship end date:
    12/01/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    SeaGen
    Topic:
    Lung Cancer
    Date added:
    08/05/2024
    Date updated:
    08/06/2024
    Relationship end date:
    12/13/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    BMS
    Topic:
    Lung Cancer
    Date added:
    08/05/2024
    Date updated:
    08/06/2024
    Relationship end date:
    08/01/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Merck
    Topic:
    Lung Cancer
    Date added:
    08/05/2024
    Date updated:
    08/06/2024
    Relationship end date:
    08/01/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Amgen
    Topic:
    Lung cancer
    Date added:
    08/05/2024
    Date updated:
    08/06/2024
    Relationship end date:
    08/01/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Catalyst
    Topic:
    Lung Cancer
    Date added:
    08/05/2024
    Date updated:
    08/06/2024
    Relationship end date:
    09/20/2023
  • Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Daiichi Sankyo
    Topic:
    Lung Cancer
    Date added:
    08/05/2024
    Date updated:
    08/06/2024
    Relationship end date:
    10/16/2024
Return to Sept. 27-28, 2024 - Symposium for Evolving Therapies and Drug Development in Oncology